Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2007

View Archived Issues

Insomnia: Clinical results of drugs under active development

Natural product shows in vitro potential to prevent diabetic cataract

Recent patents impart new therapeutics for respiratory and allergic disorders

Surface Logix new ROCK-2 inhibitor reduces kidney fibrosis in vivo

Recent patents disclose novel antiinfective agents

Positive preclinical assessment for the antidiabetic compound LY-2463665

Positive results for Theravance's phase II study of TD-5108

DelSite provides update on GelVac

Plethora completes patient enrollment for phase II study of PSD-597

Abbott and Genentech collaborate on oncology compounds

Advancis reports on FDA review of phase III trial design of Keflex PULSYS

BFTP/SEP continues funding of Immunotope cancer vaccine

Ipsen enters agreement with PregLem to develop reproductive medicines

SurModics and Merck & Co. sign ophthalmic license and research collaboration

Novel therapeutic agents for cardiovascular disorders imparted in recent patents

New phase II trial evaluates SCV-07 for HCV

Vasogen receives FDA guidance on Celacade program

UK-421045 selected for preclinical evaluation as topical antiscarring agent

Dade Behring grants sublicense to Beckman Coulter on cardiac markers

Phase II program begins for sufentanil patch

Aastrom's adult stem cell trial in critical limb ischemia begins treatment

Swedish clearance for phase III trial of K-101 for onychomycosis

Randomization targets met in two phase III trials of corifollitropin alfa

New formulation of Rebif recommended for European approval

Fertility treatment Pergoveris approved in E.U.

Supplemental NDA filed for Metvixia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...